PromarkerD secures TGA approval for software IVD and Indonesian patent
Proteomics International is pleased to announce TGA regulatory approval granted for PromarkerD software as an in vitro diagnostic (IVD) for export use, and the granting of a key PromarkerD patent in Indonesia.
Indonesia has 10.3 million adults with diabetes, which ranks the nation sixth in the International Diabetes Federation estimates for diabetes burden.
The broadening of Proteomics International’s IP portfolio reflects the ambitions to execute licensing transactions globally, the granting of the Indonesian patent secures another potentially lucrative jurisdiction.